siParadigm L.L.C

What siParadigm L.L.C does

siParadigm L.L.C is a US-based, privately-held clinical reference laboratory headquartered in Pine Brook, New Jersey, specializing in precision oncology and hematopathology diagnostics. Founded in 2003 (per firmographic records), the company operates as a CLIA-accredited and CAP-certified laboratory serving healthcare providers and physicians across the United States through a direct field-sales and online ordering model.

The company's core offering is a multi-modality diagnostic platform that combines next-generation sequencing (NGS), cytogenetics/FISH, ten-color flow cytometry, morphology/IHC, and liquid biopsy under a single reference laboratory relationship. Proprietary test brands include DeepSight(TM) Liquid Biopsy (non-invasive solid tumor genomic profiling), LymphoSight (specialized lymphoma assessment package), siFISH TC/PC (hospital-offerings FISH testing), and Concurrent Testing Offerings that allow simultaneous execution of tissue and liquid biopsy profiling. In 2025, siParadigm added Hereditary Cancer Risk Assessment Services, extending its portfolio from somatic oncology diagnostics into germline genetic risk testing. Physician workflow is supported by disease-specific clinical algorithms, specimen kits, requisition forms, and digital pathology slide viewing via an Aperio eSlide Manager (Leica Biosystems) integration.

The company generates revenue on a fee-for-service basis, billing healthcare facilities and payers for diagnostic test requisitions. Its go-to-motion is enterprise field sales to hospitals and oncology practices, supplemented by an online siPortal for test ordering and result delivery. Named customers include US Oncology, Florida Cancer Specialists, Englewood Hospital, Signature Healthcare, St. Mary's Hospital, Nyack Hospital, First Health of the Carolinas, and Brooklyn Hospital Center. No public revenue, funding, or ownership disclosures are available, and the company appears to be founder-controlled with no disclosed institutional investors.

Name

siParadigm L.L.C

Legal name

siParadigm, LLC

Website

https://siparadigm.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

101–250 employees

Short description

siParadigm is a US-based, CLIA-accredited clinical reference laboratory providing precision oncology and hematopathology diagnostics — including NGS, cytogenetics, flow cytometry, liquid biopsy, and hereditary cancer risk assessment — to hospitals and oncology practices.

Ownership category

akta.pro rank

Product category

Clinical Reference Laboratory — Oncology Diagnostics

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Oncology diagnostic services
• Molecular diagnostic testing
• Precision oncology testing
• Cytogenetic analysis services
• Liquid biopsy testing

Headquarters

HQ city

Pine Brook

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Laboratory Diagnostic Testing Services: Fee-for-service laboratory testing model providing oncology diagnostic services including genomic profiling, liquid biopsy, cytogenetics, flow cytometry, and morphology/IHC to healthcare providers and physicians. Revenue generated through test requisitions from clinical facilities.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

siParadigm is a CLIA-accredited and CAP-certified reference laboratory that performs precision oncology diagnostic testing for healthcare providers and physicians. Its offerings include solid tumor genomic profiling, liquid biopsy, hematopathology (including lymphoma assessment), cytogenetics/FISH, flow cytometry, PCR, morphology/IHC, and hereditary cancer risk assessment. The lab operates as a fee-for-service diagnostic partner with specimen pickup logistics and online ordering via its siPortal.

Product overview

siParadigm L.L.C is an oncology diagnostic reference laboratory offering a unified platform of precision medicine testing services. The portfolio centers on two core divisions: Precision Oncology (featuring Solid Tumor Genomic Profiling, DeepSight(TM) Liquid Biopsy, and Concurrent Testing Offerings) and Hematopathology (anchored by LymphoSight for lymphoma assessment). These are complemented by a comprehensive service laboratory offering Next-Generation Sequencing, Karyotyping/FISH, Flow Cytometry, and Morphology/IHC testing. The company provides physician support tools including Disease Algorithms and specimen collection kits, with digital pathology capabilities via Aperio integration. The recent addition of Hereditary Cancer Risk Assessment Services expands the preventive care offerings. All services emphasize expert consultation and evidence-based personalized medicine approaches.

Differentiator

Problem solved

Functional benefit

Brands

• DeepSight: Liquid biopsy testing service for solid tumor genomic profiling
• LymphoSight
• siFISH TC/PC
• siPortal

Products and services

• DeepSight(TM) Liquid Biopsy Non-invasive liquid biopsy testing modality that enables genomic profiling through blood samples, supporting precision oncology treatment decisions without requiring tissue biopsy. For oncologists, pathologists, and hematologists.
• Solid Tumor Genomic Profiling Comprehensive genomic profiling service for solid tumors that analyzes tumor DNA to identify actionable mutations and guide targeted therapy selection. For oncologists and cancer treatment teams.
• LymphoSight Specialized lymphoma assessment package for hematopathology diagnostics, providing comprehensive testing for hematopoietic malignancies and lymphoproliferative disorders. For hematologists, hematopathologists, and oncologists.
• siFISH TC/PC Fluorescence in situ hybridization (FISH) testing service for hospitals, enabling detection of chromosomal abnormalities in cancer diagnosis. For hospital pathology departments.
• Disease-Focused NGS Next-generation sequencing panel tests designed for specific disease categories, enabling targeted genomic analysis for diagnosis and treatment planning. For oncologists and pathologists.
• PCR Services Polymerase chain reaction testing services for molecular diagnostics, supporting detection of genetic markers in cancer and inherited conditions. For physicians and genetic counselors.
• Cytogenetics/FISH Cytogenetic analysis services including karyotyping and FISH testing to identify chromosomal abnormalities for diagnostic and prognostic purposes. For pathologists and hematologists.
• Flow Cytometry Ten-color flow cytometry analysis for immunophenotyping hematopoietic malignancies, providing phenotypic characterization with minimal specimen requirements and lower costs. For hematologists and hematopathologists.
• Morphology/IHC Expert morphological analysis and immunohistochemistry staining services for tissue examination and cancer diagnosis. For pathologists and oncologists.
• Hereditary Cancer Risk Assessment Services Genetic testing and risk assessment services for evaluating inherited cancer susceptibility, enabling preventive care and early detection strategies. For oncologists, genetic counselors, and primary care physicians.
• Concurrent Testing Offerings Integrated testing approach that allows simultaneous execution of multiple diagnostic modalities (genomic profiling, liquid biopsy, tissue analysis) to provide comprehensive patient genomic profiles. For oncologists requiring complete molecular workups.

Quantifiable outcome

• Expedited pathology diagnosis turnaround time compared to competitors

Named customers8 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Direct peers

• NeoGenomics: Specialty oncology reference laboratory offering NGS, FISH, flow cytometry, and IHC services to oncologists, pathologists, and hospitals. Direct competitor to siParadigm across the same multi-modal oncology diagnostic menu, with a substantially larger installed base of hospital and oncology customers.
• Foundation Medicine: Molecular profiling company (acquired by Roche) specializing in comprehensive genomic profiling of solid tumors and hematologic malignancies. Directly comparable to siParadigm's Solid Tumor Genomic Profiling, DeepSight(TM), and concurrent testing approach with a focus on therapy selection and clinical trial matching.
• Caris Life Sciences: Molecular diagnostics and liquid biopsy company offering comprehensive tumor profiling (MI Profile, MI Cancer Seek). Directly overlaps with siParadigm's precision oncology and liquid biopsy positioning in serving oncologists with multi-modal genomic information.
• Guardant Health: Leading liquid biopsy-focused oncology diagnostics company (Guardant360, Guardant Shield). Direct competitor to siParadigm's DeepSight(TM) liquid biopsy offering in the non-invasive solid tumor profiling category.
• Natera: Molecular diagnostics company with oncology (Signatera MRD) and hereditary cancer testing franchises. Directly comparable to siParadigm's expanded menu including the newly launched Hereditary Cancer Risk Assessment Services and tumor profiling.

Emerging players

• Tempus AI: AI-enabled precision medicine company combining next-generation sequencing with clinical and molecular data for oncology decision support. Comparable to siParadigm's diagnostic informatics platform positioning, with an AI/data-platform layer that siParadigm lacks at scale.
• Invitae: Genetic testing company with strong hereditary cancer and germline testing franchise. Directly comparable to siParadigm's newly launched Hereditary Cancer Risk Assessment Services, with broader genetic test menu reach.

Broad incumbents

• Quest Diagnostics: One of the two largest US clinical reference laboratories offering broad oncology, molecular, and anatomic pathology testing. Competes with siParadigm in the same hospital and oncology-customer segment but with a substantially wider test menu and national logistics network.
• Labcorp: Second of the dominant US national reference labs, with growing oncology and specialty molecular capabilities (post-Fortrea spin and continued specialty build-out). Overlaps with siParadigm's hospital-channel precision oncology services at scale.

Others

• BioReference Health: Specialty reference laboratory offering oncology, women's health, and urology diagnostics (an OPKO Health subsidiary). Comparable specialty reference lab model serving community physicians and hospitals with similar oncology testing services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about siParadigm L.L.C